The role of idiotype vaccines in the treatment of human B-cell malignancies

Expert Review of Vaccines

Volumn 3, Issue 2, 2004, Pages 163-170

  Bendandi, Maurizio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Clinical trials; Dendritic cells; DNA; Hybridoma; Idiotype; Lymphoma; Multiple myeloma; Recombinant protein; Soluble protein; Vaccines

Indexed keywords

CANCER VACCINE; CD20 ANTIBODY; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN; RECOMBINANT INTERFERON; RECOMBINANT PROTEIN;

ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DONOR; DRUG FORMULATION; DRUG RESPONSE; FOLLICULAR LYMPHOMA; FUTUROLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MEDICAL RESEARCH; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; DENDRITIC CELLS, FOLLICULAR; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; VACCINES, DNA;

EID: 1842635138     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.2.163     Document Type: Review

References (26)

1. Bendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev. Anticancer Ther. 1, 65-72 (2001).
2. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209-1215 (1992). The first ever demonstration that humans can be immunized against their own tumor antigens.
3. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89, 3129-3135 (1997). The series of patients immunized with idiotype vaccines featuring the longest follow-up.
4. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5, 1171-1177 (1999). A Phase II clinical trial featuring the first demonstration of vaccine-induced molecular remissions.
5. th Annual Meeting of the American Society of Hematology. San Diego, USA Abs 4953 (2003).
6. Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B-cell tumors. J. Immunol. Methods 89, 61-72 (1986).
7. nd Annual Meeting of the American Society of Hematology San Francisco, USA Abs 2481 (2000).
8. King CA, Spellerberg MB, Zhu D et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Med. 4, 1281-1286 (1998).
9. Hawkins RE, Russell SJ, Marcus R et al. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum. Gene Ther 8, 1287-1299 (1997).
10. Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62, 5845-5852 (2002).
11. McCarthy H, Ottensmeier CH, Hamblin T, Stevenson FK. Anti-idiotype vaccines. Br. J. Haematol. 123, 770-781 (2003).
12. Spelleberg MB, Zhu D, Thompsett A et al. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J. Immunol. 159, 1885-1892 (1997).
13. Inoges S, Rodriguez-Calvillo M, Lopez-Diaz de Cerio A et al. Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica 88, 1438-1440 (2003). A study comparing hybridoma-based idiotype vaccine feasibility in five different types of lymphoma in first relapse.
14. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Haematologica 84(Suppl. 1), 41-43 (1999).
15. th Annual Meeting of the American Society of Hematology. San Diego, USA Abs 357 (2003).
16. th Annual Meeting of the American Society of Hematology. San Diego, USA Abs. 358 (2003).
17. Massaia M, Borrione P, Battaglio S et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94, 673-683 (1999).
18. Coscia M, Mariani S, Battaglio S et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 18, 139-145 (2004).
19. Osterborg A, Yi Q, Henriksson L et al. Idiotype immunization combined with granulocyte macrophage colony-stimulating factor in myeloma patients induced Type I, major histocomaptibility-restricted, CD8- and CD4- specific T-cell responses. Blood 91, 2459-2466 (1998)
20. Rasmussen T, Hansson L, Osterborg A et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B-cells. Blood 101, 4607-4610 (2003).
21. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345, 1016-1020 (1995).
22. Cabrera R, Diaz-Espada F, Barrios Y et al. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma. Bone Marrow Transplant. 25, 1105-1108 (2000).
23. Kwak LW, Neelapu SS, Bishop MR. Adoptive immunotherapy with antigen-specific T-cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin. Oncol. 31, 37-46 (2004).
24. National Institutes of Health website; information on clinical research in human volunteers. www.clinicaltrials.gov Accessed 10th February, 2004
25. Genitope corporation website: www.genitope.com Accessed 12th February, 2004
26. Favrille Corporation website, clinical development stage company www.favrille.com Accessed 15th February, 2004